128 related articles for article (PubMed ID: 27366235)
1. Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best-worst scaling study.
Lynd LD; Traboulsee A; Marra CA; Mittmann N; Evans C; Li KH; Carter M; Hategekimana C
Ther Adv Neurol Disord; 2016 Jul; 9(4):287-96. PubMed ID: 27366235
[TBL] [Abstract][Full Text] [Related]
2. Parental preferences for vesicoureteral reflux treatment: Profile case best-worst scaling.
Dionise ZR; Gonzalez JM; Garcia-Roig ML; Kirsch AJ; Scales CD; Wiener JS; Purves JT; Routh JC
J Pediatr Urol; 2021 Feb; 17(1):86.e1-86.e9. PubMed ID: 33309608
[TBL] [Abstract][Full Text] [Related]
3. Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling.
Kremer IEH; Evers SMAA; Jongen PJ; Hiligsmann M
Health Expect; 2018 Feb; 21(1):171-180. PubMed ID: 28734004
[TBL] [Abstract][Full Text] [Related]
4. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy.
Peay HL; Hollin I; Fischer R; Bridges JF
Clin Ther; 2014 May; 36(5):624-37. PubMed ID: 24852596
[TBL] [Abstract][Full Text] [Related]
5. Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.
Kremer IE; Evers SM; Jongen PJ; van der Weijden T; van de Kolk I; Hiligsmann M
PLoS One; 2016; 11(11):e0164862. PubMed ID: 27812117
[TBL] [Abstract][Full Text] [Related]
6. Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.
Marshall T; Pugh A; Fairchild A; Hass S
Value Health; 2017 Dec; 20(10):1383-1393. PubMed ID: 29241898
[TBL] [Abstract][Full Text] [Related]
7. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
Poulos C; Kinter E; van Beek J; Christensen K; Posner J
Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
[TBL] [Abstract][Full Text] [Related]
8. Patient preferences in the treatment of hemophilia A: A latent class analysis.
Mühlbacher AC; Sadler A; Lamprecht B; Juhnke C
PLoS One; 2021; 16(8):e0256521. PubMed ID: 34424920
[TBL] [Abstract][Full Text] [Related]
9. Preferences for aspects of antenatal and newborn screening: a systematic review.
Vass CM; Georgsson S; Ulph F; Payne K
BMC Pregnancy Childbirth; 2019 Apr; 19(1):131. PubMed ID: 30991967
[TBL] [Abstract][Full Text] [Related]
10. Patient and caregiver preferences for the potential benefits and risks of a seizure forecasting device: A best-worst scaling.
Janse SA; Dumanis SB; Huwig T; Hyman S; Fureman BE; Bridges JFP
Epilepsy Behav; 2019 Jul; 96():183-191. PubMed ID: 31150998
[TBL] [Abstract][Full Text] [Related]
11. Preferences for Multiple Sclerosis Treatments: Using a Discrete-Choice Experiment to Examine Differences Across Subgroups of US Patients.
Mansfield C; Thomas N; Gebben D; Lucas M; Hauber AB
Int J MS Care; 2017; 19(4):172-183. PubMed ID: 28835741
[TBL] [Abstract][Full Text] [Related]
12. Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment.
Harrison M; Marra C; Shojania K; Bansback N
Rheumatology (Oxford); 2015 Oct; 54(10):1816-25. PubMed ID: 25989956
[TBL] [Abstract][Full Text] [Related]
13. Traditional attributes moo-ve over for some consumer segments: Relative ranking of fluid milk attributes.
Bir C; Widmar NO; Wolf C; Delgado MS
Appetite; 2019 Mar; 134():162-171. PubMed ID: 30550891
[TBL] [Abstract][Full Text] [Related]
14. Health State Values Derived from People with Multiple Sclerosis for a Condition-Specific Preference-Based Measure: Multiple Sclerosis Impact Scale-Eight Dimensions-Patient Version (MSIS-8D-P).
Goodwin E; Green C; Hawton A
Value Health; 2018 Nov; 21(11):1338-1345. PubMed ID: 30442282
[TBL] [Abstract][Full Text] [Related]
15. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach.
Alten R; Krüger K; Rellecke J; Schiffner-Rohe J; Behmer O; Schiffhorst G; Nolting HD
Patient Prefer Adherence; 2016; 10():2217-2228. PubMed ID: 27843301
[TBL] [Abstract][Full Text] [Related]
16. Patient Preferences in Pulmonary Arterial Hypertension, a Latent Class Analysis to Identify Preference Heterogeneity.
Mühlbacher A; Beaudet A; Brand M; Janssen EM; Gunz H; Li W; Preiss M; Sadler A; DiSantostefano RL
Value Health; 2024 Feb; 27(2):206-215. PubMed ID: 37949354
[TBL] [Abstract][Full Text] [Related]
17. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
18. Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study.
Sempere AP; Vera-Lopez V; Gimenez-Martinez J; Ruiz-Beato E; Cuervo J; Maurino J
Patient Prefer Adherence; 2017; 11():995-999. PubMed ID: 28615928
[TBL] [Abstract][Full Text] [Related]
19. Should I stay or should I go home? A latent class analysis of a discrete choice experiment on hospital-at-home.
Goossens LM; Utens CM; Smeenk FW; Donkers B; van Schayck OC; Rutten-van Mölken MP
Value Health; 2014 Jul; 17(5):588-96. PubMed ID: 25128052
[TBL] [Abstract][Full Text] [Related]
20. Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study.
Poulos C; Wakeford C; Kinter E; Mange B; Schenk T; Jhaveri M
Mult Scler J Exp Transl Clin; 2020; 6(1):2055217320910778. PubMed ID: 32215218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
